Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain

Abbas Suleiman A, Nader A, Winzenborg I, Beck D, Polepally AR, Ng J, Noertersheuser P, Mostafa NM

Published November 2020 CPT: pharmacometrics & systems pharmacology, 9(11), 639-648
DOI 10.1002/psp4.12560 PMID 32945631 PMC PMC7679073

RRM Academy Synopsis

Model predicts lower-dose elagolix cuts spine bone density 1.45% in 2 years

A model of women with endometriosis pain in four phase III studies finds that lower-dose elagolix is predicted to reduce spine bone density by 1.45% over two years. The data came from 1,684 women who had received elagolix. Race and BMI also predicted bone density at the start.

Key Findings

  • The model predicted mean lumbar spine bone density would change by −1.45% from baseline (95% CI −2.04 to −0.814) at 24 months, simulating 10,000 patients on the lower once-daily dose.
  • The predicted mean change was −0.519% at 6 months (−0.955 to −0.0885) and −0.942% at 12 months (−1.34 to −0.408); the authors describe minimal additional change in the second year.
  • The model found an exposure-response relationship between average elagolix concentration and bone density change. The concentration giving half the maximum effect on bone resorption was more than 5-fold the predicted once-daily exposure.
  • Higher body mass index, lower baseline CTX (a bone turnover marker), and African American race significantly predicted higher baseline bone density, with African American women estimated at 5% higher.
  • Higher BMI was significantly associated with higher bone formation rates. In this dataset, no tested covariate, including baseline bone density, was significantly associated with bone density changes due to elagolix.

Interpretation

The authors fitted a model to data from two randomized placebo-controlled studies and their two extension studies. The model links average elagolix concentration to bone density change. Simulating 10,000 patients gave the 24-month figure. The simulation applies to the lower of the two doses studied. The women were premenopausal with moderate-to-severe endometriosis pain. The authors judge that most women on the lower dose long term may not have clinically significant changes in bone density. They note that how these changes relate to fracture risk is unknown. AbbVie funded the work and employs all eight authors.

RRM Context

The paper describes elagolix as pain management that works by suppressing estrogen. It attributes the bone effect to that same sustained suppression. RRM looks for the cause of pelvic pain and treats the disease itself. Excision is the surgical standard for endometriosis. Medication that suppresses estrogen manages symptoms and leaves the disease in place.

Abstract

Elagolix is a novel oral gonadotropin releasing hormone receptor antagonist, that can suppress estradiol in a dose-dependent manner. It is indicated for management of moderate-to-severe pain associated with endometriosis. A population exposure-response model describing the relationship between elagolix exposure and changes in bone mineral density (BMD) was developed using data from four phase III studies in premenopausal women with endometriosis-associated pain. Elagolix pharmacokinetic exposure-dependent changes in BMD were described by an indirect-response maximum effect (Emax ) model through stimulation of bone resorption. African American race, higher body mass index (BMI), and lower type-I collagen C-telopeptide concentrations were significantly associated with higher baseline BMD. Higher BMI was significantly associated with higher bone formation rates. Simulations using the final model demonstrated that elagolix 150 mg q.d. dosing for 24 months is predicted to result in -1.45% (-2.04 to -0.814) decrease from baseline in BMD and were used to support corresponding dosing recommendations in the label.

Related research

Ahmed Abbas Suleiman, Ahmed Nader, Insa Winzenborg, Denise Beck, Akshanth R Polepally, Juki Ng, Peter Noertersheuser, Nael M Mostafa
A Suleiman, A Nader, I Winzenborg, D Beck, A Polepally, J Ng, Pete Noertersheuser, P Noertersheuser, N Mostafa
PMID 32945631 32945631 DOI 10.1002/psp4.12560 10.1002/psp4.12560 Abbas Suleiman et al. 2020, Abbas Suleiman 2020